A Southeastern Cancer Study Group Phase I/II trial with vaccinia melanoma oncolysates

M. K. Wallack, K. R. McNally, E. Leftheriotis, H. Seigler, Charles M. Balch, H. Wanebo, A. A. Bartolucci, J. A. Bash

Research output: Contribution to journalArticle

Abstract

Vaccinia melanoma oncolysates (VMO) were tested in a Southeastern Cancer Study Group (SECSG) Phase I/II trial. Forty-eight patients with high-risk Stage I or pathologic Stage II disease were placed on study at six different dose levels and two different treatment regimens. Patients were monitored for toxicity to the VMO after each injection. Patients' sera were tested for anti-human melanoma reactivity with the Staphylococcus Protein A (SpA) assay. Toxicity was minimal at all doses tested. In only 2 of 19 patients on delayed treatment did reactivity develop in the SpA assay by 6 months. However, 13 of 23 patients on immediate treatment showed reactivity, including 8 of 8 at the two highest doses. Since the VMO appears to be safe at all of the doses tested, and because of the immunogenicity of the VMO at the higher doses as demonstrated by the SpA asasy, the 2-mg dose level, for immediate treatment, was chosen for use in future trials.

Original languageEnglish (US)
Pages (from-to)649-655
Number of pages7
JournalCancer
Volume57
Issue number3
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

Vaccinia
Melanoma
Staphylococcal Protein A
Staphylococcus
Neoplasms
Therapeutics
Injections
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A Southeastern Cancer Study Group Phase I/II trial with vaccinia melanoma oncolysates. / Wallack, M. K.; McNally, K. R.; Leftheriotis, E.; Seigler, H.; Balch, Charles M.; Wanebo, H.; Bartolucci, A. A.; Bash, J. A.

In: Cancer, Vol. 57, No. 3, 1986, p. 649-655.

Research output: Contribution to journalArticle

Wallack, MK, McNally, KR, Leftheriotis, E, Seigler, H, Balch, CM, Wanebo, H, Bartolucci, AA & Bash, JA 1986, 'A Southeastern Cancer Study Group Phase I/II trial with vaccinia melanoma oncolysates', Cancer, vol. 57, no. 3, pp. 649-655. https://doi.org/10.1002/1097-0142(19860201)57:3<649::AID-CNCR2820570342>3.0.CO;2-6
Wallack, M. K. ; McNally, K. R. ; Leftheriotis, E. ; Seigler, H. ; Balch, Charles M. ; Wanebo, H. ; Bartolucci, A. A. ; Bash, J. A. / A Southeastern Cancer Study Group Phase I/II trial with vaccinia melanoma oncolysates. In: Cancer. 1986 ; Vol. 57, No. 3. pp. 649-655.
@article{4c1d4814bf2d41a4b308b784942f44f4,
title = "A Southeastern Cancer Study Group Phase I/II trial with vaccinia melanoma oncolysates",
abstract = "Vaccinia melanoma oncolysates (VMO) were tested in a Southeastern Cancer Study Group (SECSG) Phase I/II trial. Forty-eight patients with high-risk Stage I or pathologic Stage II disease were placed on study at six different dose levels and two different treatment regimens. Patients were monitored for toxicity to the VMO after each injection. Patients' sera were tested for anti-human melanoma reactivity with the Staphylococcus Protein A (SpA) assay. Toxicity was minimal at all doses tested. In only 2 of 19 patients on delayed treatment did reactivity develop in the SpA assay by 6 months. However, 13 of 23 patients on immediate treatment showed reactivity, including 8 of 8 at the two highest doses. Since the VMO appears to be safe at all of the doses tested, and because of the immunogenicity of the VMO at the higher doses as demonstrated by the SpA asasy, the 2-mg dose level, for immediate treatment, was chosen for use in future trials.",
author = "Wallack, {M. K.} and McNally, {K. R.} and E. Leftheriotis and H. Seigler and Balch, {Charles M.} and H. Wanebo and Bartolucci, {A. A.} and Bash, {J. A.}",
year = "1986",
doi = "10.1002/1097-0142(19860201)57:3<649::AID-CNCR2820570342>3.0.CO;2-6",
language = "English (US)",
volume = "57",
pages = "649--655",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - A Southeastern Cancer Study Group Phase I/II trial with vaccinia melanoma oncolysates

AU - Wallack, M. K.

AU - McNally, K. R.

AU - Leftheriotis, E.

AU - Seigler, H.

AU - Balch, Charles M.

AU - Wanebo, H.

AU - Bartolucci, A. A.

AU - Bash, J. A.

PY - 1986

Y1 - 1986

N2 - Vaccinia melanoma oncolysates (VMO) were tested in a Southeastern Cancer Study Group (SECSG) Phase I/II trial. Forty-eight patients with high-risk Stage I or pathologic Stage II disease were placed on study at six different dose levels and two different treatment regimens. Patients were monitored for toxicity to the VMO after each injection. Patients' sera were tested for anti-human melanoma reactivity with the Staphylococcus Protein A (SpA) assay. Toxicity was minimal at all doses tested. In only 2 of 19 patients on delayed treatment did reactivity develop in the SpA assay by 6 months. However, 13 of 23 patients on immediate treatment showed reactivity, including 8 of 8 at the two highest doses. Since the VMO appears to be safe at all of the doses tested, and because of the immunogenicity of the VMO at the higher doses as demonstrated by the SpA asasy, the 2-mg dose level, for immediate treatment, was chosen for use in future trials.

AB - Vaccinia melanoma oncolysates (VMO) were tested in a Southeastern Cancer Study Group (SECSG) Phase I/II trial. Forty-eight patients with high-risk Stage I or pathologic Stage II disease were placed on study at six different dose levels and two different treatment regimens. Patients were monitored for toxicity to the VMO after each injection. Patients' sera were tested for anti-human melanoma reactivity with the Staphylococcus Protein A (SpA) assay. Toxicity was minimal at all doses tested. In only 2 of 19 patients on delayed treatment did reactivity develop in the SpA assay by 6 months. However, 13 of 23 patients on immediate treatment showed reactivity, including 8 of 8 at the two highest doses. Since the VMO appears to be safe at all of the doses tested, and because of the immunogenicity of the VMO at the higher doses as demonstrated by the SpA asasy, the 2-mg dose level, for immediate treatment, was chosen for use in future trials.

UR - http://www.scopus.com/inward/record.url?scp=0022620352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022620352&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19860201)57:3<649::AID-CNCR2820570342>3.0.CO;2-6

DO - 10.1002/1097-0142(19860201)57:3<649::AID-CNCR2820570342>3.0.CO;2-6

M3 - Article

C2 - 3943002

AN - SCOPUS:0022620352

VL - 57

SP - 649

EP - 655

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -